Hidden in Plain Sight: How CJD Patients in Newark Are Spending Months Treating the Wrong Disease
For many Newark-area families, the journey toward a CJD diagnosis does not begin with a neurologist ordering the right test. It begins with a different diagnosis entirely — one that feels plausible at first, carries its own treatment protocol, and delays the critical window for identifying prion disease. By the time the correct answer arrives, weeks or months may have passed. In a disease that can progress from first symptom to death in under a year, that delay is not a minor inconvenience. It can define the entire course of a patient's remaining life.
The pattern is consistent enough that clinicians at Newark CJD Center have begun referring to it informally as the misdiagnosis interval — the stretch of time between when symptoms first appear and when CJD is formally considered. Understanding what fills that interval, and why, is essential for any family navigating unexplained neurological decline.
Why CJD Looks Like Something Else
Creutzfeldt-Jakob disease is, by its nature, a diagnostic impersonator. Its early symptoms — cognitive slowing, mood changes, balance problems, visual disturbances, and subtle memory disruption — overlap substantially with conditions that clinicians encounter far more frequently in everyday practice. When a 68-year-old Newark patient presents with progressive forgetfulness and personality shifts, Alzheimer's disease is statistically the most reasonable first assumption. When a 72-year-old arrives with tremor, rigidity, and slowed movement, Parkinson's disease dominates the differential.
This is not a failure of intelligence on the part of treating physicians. It is a failure of probability. CJD is rare — affecting roughly one to two people per million annually — while Alzheimer's and Parkinson's together affect millions of Americans. Clinicians are trained, reasonably, to consider common diagnoses before rare ones. The problem arises when the clinical picture begins to deviate from those common diagnoses and no one recalibrates.
Dr. Miriam Okafor, a neurologist affiliated with a Newark-area academic medical center who has consulted on several confirmed CJD cases, described the challenge plainly: "The early presentations of CJD and Alzheimer's can be nearly indistinguishable in the first office visit. What separates them is velocity. CJD moves at a pace that Alzheimer's simply does not. When a patient who seemed mildly forgetful in January is unable to walk independently by April, that speed should force a reassessment."
The Three Most Common Misdiagnosis Categories
Alzheimer's accounts for the largest share of initial misdiagnoses in CJD patients seen at Newark CJD Center. The cognitive symptoms — memory impairment, difficulty with language, confusion, and disorientation — are genuinely shared between the two conditions in their early phases. What distinguishes CJD is the rate of deterioration and the eventual emergence of motor symptoms, including myoclonus (involuntary muscle jerks), cerebellar ataxia, and in some cases, the characteristic startle response. Families often report that their loved one was placed on Alzheimer's medications for months before a clinician noted the atypical speed of decline.
Parkinson's Disease and Related Movement Disorders
CJD's motor manifestations — rigidity, gait instability, and bradykinesia — can closely mimic Parkinson's disease, particularly in older patients. Some variants of CJD, including the Heidenhain variant, present with prominent visual symptoms and cortical blindness, which may further complicate the picture. Patients in this misdiagnosis category often receive dopaminergic therapies that produce no meaningful improvement, a pattern that, if recognized early, could itself prompt reconsideration of the diagnosis.
Psychiatric Illness
This category is perhaps the most troubling, because psychiatric misdiagnosis carries its own set of downstream consequences. In younger patients with variant CJD, or in those whose presentation skews toward behavioral and mood changes rather than motor symptoms, the initial diagnosis is sometimes depression, anxiety, or even psychosis. Patients in this group may be referred to psychiatrists, started on antipsychotic or antidepressant regimens, and in some cases admitted to inpatient psychiatric facilities before neurological disease is considered. The diagnostic delay in this subgroup tends to be the longest, and the emotional cost to families is compounded by stigma.
How Long Does the Misdiagnosis Interval Last?
Based on case reviews and clinical consultations conducted through Newark CJD Center, the misdiagnosis interval in local patients has ranged from four weeks to as long as seven months. The median falls somewhere around two to three months — a period during which patients may undergo treatments that are ineffective at best and, in some cases, carry their own risks.
Several factors extend this interval. Fragmented care — a persistent structural problem in the Newark metropolitan area — means that a patient's primary care physician, neurologist, and specialist may not be sharing records efficiently. A clinician who sees the patient six weeks after the initial evaluation may not have access to documentation showing how dramatically the patient has changed. Each provider, working from a snapshot rather than a timeline, continues treating the original diagnosis.
Red Flags That Should Prompt Reconsideration
Neurologists consulted by Newark CJD Center identified several clinical patterns that should trigger urgent reconsideration of a working diagnosis:
- Unusually rapid progression: Any dementia or movement disorder that advances noticeably over weeks rather than months should raise concern.
- Myoclonus: Sudden, brief muscle jerks — particularly if they appear alongside cognitive symptoms — are a significant red flag for prion disease.
- Visual disturbances: Unexplained vision changes, double vision, or cortical blindness accompanying cognitive decline warrant a broader workup.
- Failure to respond to standard treatment: A Parkinson's patient who does not respond to levodopa, or an Alzheimer's patient whose decline seems to outpace the expected trajectory, deserves a reassessment.
- Cerebellar signs: Gait ataxia and coordination problems in conjunction with dementia are not typical of common neurodegenerative diseases.
What Families Can Do Right Now
Advocating effectively within a complex medical system is difficult under ordinary circumstances. When a loved one's condition is deteriorating rapidly, it can feel nearly impossible. Still, there are concrete steps families can take.
First, document everything. Keep a written log of symptoms, noting not just what is present but when each symptom appeared and how quickly it has changed. This timeline is often the most persuasive tool in prompting a physician to reconsider a diagnosis.
Second, request specific testing. Cerebrospinal fluid analysis for 14-3-3 protein and real-time quaking-induced conversion (RT-QuIC) testing, MRI with diffusion-weighted imaging, and EEG are among the diagnostic tools that can help distinguish CJD from other conditions. Families should not hesitate to ask whether these tests have been ordered and, if not, why.
Third, seek a second opinion from a center with prion disease expertise. Newark CJD Center provides consultative services for patients and families with concerns about prion disease, and national prion disease referral centers — including those affiliated with the National Prion Disease Pathology Surveillance Center — are available to assist in complex diagnostic cases.
Finally, trust the trajectory. If a diagnosis was made months ago and the patient's condition has deteriorated far faster than that diagnosis would predict, that discrepancy is itself clinical information. Bring it to the attention of every provider involved in your loved one's care.
A System That Can Do Better
The misdiagnosis of CJD is not inevitable. It is, in many cases, a product of low disease awareness, fragmented care systems, and the understandable tendency to favor common explanations. Greater familiarity with CJD's distinguishing features — particularly the velocity of its progression — can meaningfully shorten the diagnostic interval and allow patients and families to make informed decisions about care, research participation, and end-of-life planning while time remains.
Newark CJD Center remains committed to improving diagnostic accuracy across the region, through clinician education, consultative support, and ongoing research into the earliest detectable markers of prion disease. If you believe your loved one's diagnosis does not fully account for the clinical picture you are witnessing, we encourage you to reach out. Early and accurate diagnosis is not only possible — it is worth fighting for.
